Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients

AIDS

Volumn 19, Issue 15, 2005, Pages 1607-1615

  Thompson, Melanie A ^a   Kessler, Harold A ^b   Eron Jr , Joseph J ^c   Jacobson, Jeffrey M ^d   Adda, Nathalie ^e   Shen, Gong ^e   Zong, Jian ^e   Harris, Jeanette ^e   Moxham, Gary ^e   Rousseau, Franck S ^e  

^a AIDS Research Consortium   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e GILEAD SCIENCES INC   (United States)

Author keywords

AIDS; Amdoxovir; DAPD; HIV

Indexed keywords

AMDOXOVIR; GUANOSINE DERIVATIVE; RNA;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUTATION; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; T LYMPHOCYTE; VIRUS LOAD;

EID: 27144445999     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000186822.68606.05     Document Type: Article

References (24)

1. Turner D, Brenner B, Wainberg MA. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 2004; 53:53-57.
2. Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, et al., the EuroSIDA study group. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002; 7:21-30.
3. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
4. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
5. Walmsley S. Individualized therapy for the treatment-experienced patient. AIDS Read 2003; 13 (6 Suppl):S11-S15.
6. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
7. Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003; 8:489-506.
8. Deeks SC. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362 (9400):2002-2011.
9. Jeffrey JL, Feng JY, Qi CC, Anderson KS, Furman PA. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. J Biol Chem 2003; 278:18971-18979.
10. Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B, et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J Acquir Immune Defic Syndr 2002; 29:11-20.
11. Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, de Muys JM, Bowlin TL, et al. Mechanism of action and in vitro activity of 1′, 3′- dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother 1999; 43:2376-2382.
12. Bloor S, Kemp SD, Hertogs K, Alcorn T, Larder BA. Patterns of HIV drug resistance in routine clinical practice: a survey of almost 12,000 samples from the USA in 1999 [abstract 169]. Antivir Ther 2000; 5:132.
13. Lanier ER, Scott J, Ait-Khaled M, et al. Prevalence of mutations associated with resistance to antiretroviral therapy from 1999-2002 [poster 635]. In: Programs and Abstracts of the 10th Conference on Retrovirus and Opportunistic Infections (Boston). Arlington, VA: Foundation for Retrovirology and Human Health, 2003. p. 285.
14. Rousseau FS, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, et al., FTC-102 Clinical Trial Group. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003; 188:1652-1658.
15. Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001; 48:507-513.
16. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373 (6510):123-126.
17. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373 (6510):117-122.
18. Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, Mellors JW. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 2000; 44:1783-1788.
19. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001; 6 (Suppl 3): 25-44.
20. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
21. Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, et al. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. J Antimicrob Chemother 2004; 53: 89-94.
22. Barrios A, de Mendoza C, Martin-Carbonero L, Ribera E, Domingo P, Galindo MJ, et al. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. J Clin Microbiol 2003; 41:4421-4423.
23. McColl DJ, Miller MD. The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. J Antimicrob Chemother 2003; 51:219-223.
24. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846.